Published in Recenti Prog Med on May 01, 2002
Lipid profile in leukemia and Hodgkin's disease. Indian J Clin Biochem (2006) 0.79
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Preconditioning of low-frequency repetitive transcranial magnetic stimulation with transcranial direct current stimulation: evidence for homeostatic plasticity in the human motor cortex. J Neurosci (2004) 2.68
Abnormal associative plasticity of the human motor cortex in writer's cramp. Brain (2003) 2.57
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44
Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex. Dev Cell (2009) 2.40
Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell (2013) 2.33
Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol (2012) 1.81
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res (2002) 1.69
Acute remapping within the motor system induced by low-frequency repetitive transcranial magnetic stimulation. J Neurosci (2003) 1.62
Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma (2010) 1.46
Homeostatic-like plasticity of the primary motor hand area is impaired in focal hand dystonia. Brain (2005) 1.41
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother (2009) 1.36
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother (2013) 1.30
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol (2007) 1.30
Effects on the right motor hand-area excitability produced by low-frequency rTMS over human contralateral homologous cortex. J Physiol (2003) 1.28
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res (2007) 1.23
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother (2011) 1.19
Distinct changes in cortical and spinal excitability following high-frequency repetitive TMS to the human motor cortex. Exp Brain Res (2004) 1.16
Rapid-rate paired associative stimulation of the median nerve and motor cortex can produce long-lasting changes in motor cortical excitability in humans. J Physiol (2006) 1.15
Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm. J Neurosci (2006) 1.14
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol (2011) 1.07
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res (2004) 1.03
Clinical features of dystonia: a pathophysiological revisitation. Curr Opin Neurol (2008) 0.98
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol (2007) 0.94
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol (2010) 0.91
Long lasting effects of transcranial direct current stimulation on motor imagery. Neuroreport (2004) 0.91
Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol (2003) 0.91
Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorg Med Chem (2012) 0.90
Posterior parietal rTMS disrupts human Path Integration during a vestibular navigation task. Neurosci Lett (2008) 0.90
Unilateral cerebellar stroke disrupts movement preparation and motor imagery. Clin Neurophysiol (2006) 0.89
Integration of functional neuroimaging in CyberKnife radiosurgery: feasibility and dosimetric results. Neurosurg Focus (2013) 0.89
Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. Bioorg Med Chem (2009) 0.89
A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun Mass Spectrom (2004) 0.88
Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol (2012) 0.87
Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol (2004) 0.87
The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest (2014) 0.86
Navigated transcranial magnetic stimulation for "somatotopic" tractography of the corticospinal tract. Neurosurgery (2014) 0.86
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. J Cell Physiol (2002) 0.86
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol (2013) 0.85
Brain-derived neurotrophic factor--a major player in stimulation-induced homeostatic metaplasticity of human motor cortex? PLoS One (2013) 0.85
Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis. Bioorg Med Chem (2012) 0.85
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Acta Haematol (2009) 0.84
Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol (2009) 0.84
Structural basis for bivalent Smac-mimetics recognition in the IAP protein family. J Mol Biol (2009) 0.84
Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles. J Mol Biol (2008) 0.84
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res (2013) 0.84
Is central fatigue in multiple sclerosis a disorder of movement preparation? J Neurol (2010) 0.84
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol (2011) 0.83
MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol (2014) 0.83
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol (2010) 0.82
Early impairment of synaptic plasticity in patients with Down's syndrome. Neurobiol Aging (2007) 0.82
Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol (2010) 0.82
Stiffness as a presenting symptom of an odd clinical condition caused by multiple sclerosis and myotonia congenita. Neuromuscul Disord (2012) 0.81
Perceptual encoding of self-motion duration in human posterior parietal cortex. Ann N Y Acad Sci (2009) 0.81
Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine (2008) 0.81
Impairment of sensory-motor plasticity in mild Alzheimer's disease. Brain Stimul (2012) 0.81
Motor cortex abnormalities in amyotrophic lateral sclerosis with transcranial direct-current stimulation. Muscle Nerve (2007) 0.80
Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol (2010) 0.80
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol (2012) 0.80
Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest (2013) 0.80
Structure revision of the lantibiotic 97518. J Nat Prod (2009) 0.80
Corticospinal excitability during motor imagery of a simple tonic finger movement in patients with writer's cramp. Mov Disord (2005) 0.80
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother (2010) 0.80
Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol (2009) 0.79
Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res (2012) 0.79
Cardiac involvement in patients with hematologic malignancies. J Investig Med (2010) 0.79
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol (2011) 0.78
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. Leuk Lymphoma (2004) 0.78
Cognitive processess and cognitive reserve in multiple sclerosis. Arch Ital Biol (2015) 0.78
Successful treatment of Holmes tremor by levetiracetam. Mov Disord (2008) 0.78
Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol (2005) 0.78
Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem (2011) 0.78
Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma (2007) 0.78
Reduction in IL-33 plasma levels might be involved in T cell dysregulation in chronic lymphocytic leukemia. Acta Haematol (2013) 0.78
Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. Acta Oncol (2011) 0.78
Cortical processing in vestibular navigation. Prog Brain Res (2008) 0.78
Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Oncol Rep (2010) 0.77
Brain dysfunction in uremia: a question of cortical hyperexcitability? Clin Neurophysiol (2005) 0.77
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci (2012) 0.77
Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol (2012) 0.77
Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases. Tumori (2009) 0.76
A local signature of LTP-like plasticity induced by repetitive paired associative stimulation. Brain Topogr (2014) 0.76
Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates. J Oral Maxillofac Surg (2009) 0.76